Nanotherapeutic approach to tackle chemotherapeutic resistance of cancer stem cells

Oliveira, Bruna Stefane Alves de; Assis, Ana Carolina Correa de; Souza, Natália Melo; Ferreira, Luiz Fernando Romanholo; Soriano, Renato Nery; Bilal, Muhammad; Iqbal, Hafiz M.N.

doi:10.1016/j.lfs.2021.119667

Cited by 9 publications

(6 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inhibition of cancer cell proliferation is a multifactorial process that might occur due to the accumulation/efflux of the cytotoxic agent and the genetic makeup of the cancer cells, among other factors [ 74 , 75 ]. The results indicate that the observed time-dependent decrease in cell viability could be due to an increase in the cellular uptake of DOX released from DOX/opt CH after prolonged exposure.…”

Section: Resultsmentioning

confidence: 99%

Graphene Oxide/Chitosan Injectable Composite Hydrogel for Controlled Release of Doxorubicin: An Approach for Enhanced Intratumoral Delivery

et al. 2022

View full text Add to dashboard Cite

Intratumoral (IT) injection of chemotherapeutics into needle-accessible solid tumors can directly localize the anticancer drug in the tumor site, thus increasing its local bioavailability and reducing its undesirable effects compared to systemic administration. In this study, graphene oxide (GO)-based chitosan/β-glycerophosphate (CS/GP) thermosensitive injectable composite hydrogels (CH) were prepared and optimized for the localized controlled delivery of doxorubicin (DOX). A quality-by-design (QbD) approach was used to study the individual and combined effects of several formulation variables to produce optimal DOX-loaded GO/CS/GP CH with predetermined characteristics, including gelation time, injectability, porosity, and swelling capacity. The surface morphology of the optimal formulation (DOX/opt CH), chemical interaction between its ingredients and in vitro release of DOX in comparison to GO-free CS/GP CH were investigated. Cell viability and cellular uptake after treatment with DOX/opt CH were studied on MCF 7, MDB-MB-231 and FaDu cell lines. The statistical analysis of the measured responses revealed significant effects of the concentration of GO, the concentration of CS, and the CS:GP ratio on the physicochemical characteristics of the prepared GO/CS/GP CH. The optimization process showed that DOX-loaded GO/CS/GP CH prepared using 0.1% GO and 1.7% CS at a CS: GO ratio of 3:1 (v/v) had the highest desirability value. DOX/opt CH showed a porous microstructure and chemical compatibility between its ingredients. The incorporation of GO resulted in an increase in the ability of the CH matrices to control DOX release in vitro. Finally, cellular characterization showed a time-dependent increase in cytotoxicity and cellular uptake of DOX after treatment with DOX/opt CH. The proposed DOX/opt CH might be considered a promising injectable platform to control the release and increase the local bioavailability of chemotherapeutics in the treatment of solid tumors.

show abstract

Section: Resultsmentioning

confidence: 99%

Graphene Oxide/Chitosan Injectable Composite Hydrogel for Controlled Release of Doxorubicin: An Approach for Enhanced Intratumoral Delivery

et al. 2022

View full text Add to dashboard Cite

show abstract

“…After that, the collected lncRNAs were acquired to establish the SRLncSig risk score model with Lasso regression analyses. Since stemness was acknowledged as an important cause of chemotherapy resistance (Grandits and Wieser, 2021;Liu et al, 2021;Marimuthu et al, 2021;Narusaka et al, 2021;Oliveira et al, 2021;Panicker et al, 2021), the SRLncSig was firstly tested for its predictive value for chemotherapy response. Higher SRLncSig score was revealed with lower IC50, suggesting a superior chemotherapy response for the high-risk group.…”

Section: Discussionmentioning

confidence: 99%

Integrated Analysis of Stemness-Related LncRNAs Helps Predict the Immunotherapy Responsiveness of Gastric Cancer Patients

Jiang

Chen

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The immune microenvironment plays a critical role in tumor biology. As a critical feature of cancers, stemness is acknowledged as a contributor to the development of drug resistance in gastric cancers (GCs). Long non-coding RNAs (lncRNAs) have been revealed to participate in this process. In this study, we aimed to develop a stemness-related lncRNA signature (SRLncSig) with guiding significance for immunotherapy. Three cohorts (TCGA, Zhongshan, and IMvigor210) were enrolled for analysis. A list of stemness-related lncRNAs (SRlncRNAs) was collected by co-expression strategy under the threshold of coefficient value >0.35 and p-value < 0.05. Cox and Lasso regression analysis was further applied to find out the SRlncRNAs with prognosis-predictive value to establish the SRLncSig in the TCGA cohort. IPS and TIDE algorithms were further applied to predict the efficacy of SRLncSig in TCGA and Zhongshan cohorts. IMvigor210 was composed of patients with clinical outcomes of immunotherapy. The results indicated that SRLncSig not only was confirmed as an independent risk factor for GCs but also identified as a robust indicator for immunotherapy. The patient with a lower SRLncSig score was more likely to benefit from immunotherapy, and the results were highly consistent in three cohorts. In conclusion, our study not only could clarify the correlations between stemness and immunotherapy in GC patients but also provided a model to guide the applications of immunotherapy in clinical practice.

show abstract

“…One view is that CSCs have the same characteristics as stem cells and, therefore, may be derived from the gene mutations of normal stem cells. Another idea is that they are dedifferentiated from cancer cells, including cancer cell lines and patient tumor tissues [ 15 ]. Recent studies have shown that the reprogramming mechanism can convert differentiated tumor cells into CSCs, and even produce CSCs with different characteristics.…”

Section: Cscsmentioning

confidence: 99%

“…To solve its drug resistance, it is necessary to start from multiple aspects and apply multiple methods in combination. A single way to control its drug resistance effect is unsatisfactory [ 15 , 21 – 23 ].…”

Section: Cscsmentioning

confidence: 99%

Targeting cancer stem cells with polymer nanoparticles for gastrointestinal cancer treatment

Sun

Cao

et al. 2022

Stem Cell Res Ther

View full text Add to dashboard Cite

Nanomaterials are developing rapidly in the medical field, bringing new hope for treating various refractory diseases. Among them, polymer nanomaterials, with their excellent properties, have been used to treat various diseases, such as malignant tumors, diabetes, and nervous system diseases. Gastrointestinal cancer is among the cancers with the highest morbidity and mortality worldwide. Cancer stem cells are believed to play an important role in the occurrence and development of tumors. This article summarizes the characteristics of gastrointestinal cancer stem cells and reviews the latest research progress in treating gastrointestinal malignant tumors using polymer nanoparticles to target cancer stem cells. In addition, the review article highlights the potential of polymer nanoparticles in targeting gastrointestinal cancer stem cells.

show abstract

Nanotherapeutic approach to tackle chemotherapeutic resistance of cancer stem cells

Cited by 9 publications

References 151 publications

Graphene Oxide/Chitosan Injectable Composite Hydrogel for Controlled Release of Doxorubicin: An Approach for Enhanced Intratumoral Delivery

Graphene Oxide/Chitosan Injectable Composite Hydrogel for Controlled Release of Doxorubicin: An Approach for Enhanced Intratumoral Delivery

Integrated Analysis of Stemness-Related LncRNAs Helps Predict the Immunotherapy Responsiveness of Gastric Cancer Patients

Targeting cancer stem cells with polymer nanoparticles for gastrointestinal cancer treatment

Contact Info

Product

Resources

About